EDGAR Filing Documents for 0001193125-17-056301

Form 8-K - Current report:

SEC Accession No. 0001193125-17-056301

Filing Date

2017-02-24

Accepted

2017-02-24 16:05:33

Documents

Period of Report

2017-02-23

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	d336393d8k.htm	8-K	15612
2	EX-4.1	d336393dex41.htm	EX-4.1	556685
3	GRAPHIC	g336393pic60.jpg	GRAPHIC	5352
4	GRAPHIC	g336393pic61.jpg	GRAPHIC	5333
5	GRAPHIC	g336393pic63.jpg	GRAPHIC	5688
6	GRAPHIC	g336393pic63a.jpg	GRAPHIC	5842
7	GRAPHIC	g336393pic65.jpg	GRAPHIC	5319
8	GRAPHIC	g336393pic66.jpg	GRAPHIC	6033
	Complete submission text file	0001193125-17-056301.txt		620132

Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037

Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600

Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)